Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need ...
Spruce Biosciences, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, announced ...
Presentations Highlight Potential Benefits of Therapies Incorporating J-Brain Cargo®, JCR’s Proprietary, Blood-Brain Barrier-Penetrating Technology -HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals ...
JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR"), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced the presentation of four ...
Shareholder/Analyst Call February 5, 2026 3:30 PM ESTCompany ParticipantsRyan Watts - Co-Founder, President, CEO ...
Clinical Trials Arena on MSN
Ultragenyx’s gene therapy shows sustained improvements in MPS IIIA
There are currently no approved disease-modifying therapies for MPS IIIA.
Researchers explored how infants act purposefully by attaching a colorful mobile to their foot and tracking movements with a Vicon 3D motion capture system. The study tested AI's ability to detect ...
Since 6 January 2026, a total of 31 infant formula products of various brands have been recalled in Luxembourg due to a contaminated ingredient. The ingredient in question is an omega-6 fatty acid ...
“It really tells us that infants are interacting with the world in a lot more complex of a way than we might imagine,” said ...
Human evolution has long been tied to growing brain size, and new research suggests prenatal hormones may have played a surprising role. By studying the relative lengths of index and ring fingers — a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results